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Abstract
Background: The histone-like Hlp protein is emerging as a key component in mycobacterial
pathogenesis, being involved in the initial events of host colonization by interacting with laminin and
glycosaminoglycans (GAGs). In the present study, nuclear magnetic resonance (NMR) was used to
map the binding site(s) of Hlp to heparan sulfate and identify the nature of the amino acid residues
directly involved in this interaction.
Results: The capacity of a panel of 30 mer synthetic peptides covering the full length of Hlp to bind
to heparin/heparan sulfate was analyzed by solid phase assays, NMR, and affinity chromatography.
An additional active region between the residues Gly46 and Ala60 was defined at the N-terminal
domain of Hlp, expanding the previously defined heparin-binding site between Thr31 and Phe50.
Additionally, the C-terminus, rich in Lys residues, was confirmed as another heparan sulfate binding
region. The amino acids in Hlp identified as mediators in the interaction with heparan sulfate were
Arg, Val, Ile, Lys, Phe, and Thr.
Conclusion: Our data indicate that Hlp interacts with heparan sulfate through two distinct regions
of the protein. Both heparan sulfate-binding regions here defined are preserved in all mycobacterial
Hlp homologues that have been sequenced, suggesting important but possibly divergent roles for
this surface-exposed protein in both pathogenic and saprophic species.
Background
Leprosy and tuberculosis constitute age-old infectious dis-
eases that have affected human beings for millennium.
Leprosy, caused by Mycobacterium leprae, continues to be a
significant public health problem in several developing
countries, including Brazil, and is responsible for the leg-
acy of millions of individuals with permanent physical
deformities [1]. On the other hand, tuberculosis, caused
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by Mycobacterium tuberculosis has most likely killed more
human beings than any other disease in history, at an
average of 4 individuals per minute worldwide [2]. One
major reason for the failure to eradicate these diseases
may be closely related to the absence of effective vaccines
since BCG, the only one available against both leprosy
and tuberculosis, has displayed highly variable protection
rates around the world [3]. Mycobacteria are intracellular
pathogens that preferentially infect mononuclear phago-
cytes although other cell types such as epithelial and
endothelial cells are also colonized during disease dissem-
ination [4]. M. leprae, also found inside Schwann cells of
the peripheral nervous system, is responsible for the nerve
damage observed in leprosy [5]. Mycobacteria are Gram-
positive bacteria presenting a very complex and unique
cell wall structure, which seems to play a major role in
their pathogenesis. Deciphering the mechanisms impli-
cated in mycobacterial pathogenesis remains a major
challenge for leprosy and tuberculosis research, which will
hopefully lead to the development of new, more effective
prophylactic and/or therapeutic strategies.
During infection, a critical early event is the adherence of
the microorganism to the target tissues within the host.
Adhesion is accomplished by specific molecular interac-
tions involving adhesins on the bacterial surface and
receptors on the surface of the host cell. The histone-like
Hlp protein is a positively-charged, surface-exposed mol-
ecule recently implicated in the attachment of pathogenic
mycobacteria to host cells. This protein was initially
described as a laminin-binding protein (LBP) involved in
M. leprae-Schwann cell interaction. [6,7]. More recently
Hlp has been shown to also play a major role in mediating
the adhesion of mycobacteria to epithelial respiratory
cells by interacting with proteoglycan-containing recep-
tors such as heparan sulfate and hyaluronic acid [8,9].
Mycobacterial Hlp, roughly twice the size of other bacte-
rial histone-like proteins, is a highly conserved protein
shared by all mycobacterial species. The N-terminal half
of mycobacterial Hlp containing the prokaryotic DNA-
binding motif shares significant homology with the his-
tone-like HU proteins found in Escherichia coli and the HB
proteins in Bacillus subtilis, respectively. The C-terminal
half of mycobacterial Hlp, absent in most bacteria, has an
unusual amino acid composition owing to a high alanine,
lysine, and proline content resembling the C-terminal
region of eukaryotic class H1 histones [10]. Initial studies
by Aoki et al [9] have mapped the heparin-binding site of
Hlp (so-called MDP1) in the N-terminal region between
Thr31 and Phe50 overlapping the previously defined
DNA-binding region [11]. However, after testing the trun-
cated recombinant Hlp molecules corresponding to the
N-terminal (rHlp-N) and the C-terminal (rHlp-C)
domains of the protein, we recently found that the inter-
action of Hlp/LBP with laminin and heparin was for the
most part mediated by the C-terminal domain of the pro-
tein. Moreover, the same domain was found to be
involved in Hlp/LBP-mediating bacterial binding to
human Schwann cells [12]. It is clear that additional stud-
ies are needed to more precisely define the interacting
regions of Hlp/LBP with glycosaminoglycans (GAG).
In the present report, the interaction of Hlp with heparan
sulfate was further investigated by using a panel of 30-mer
synthetic peptides covering the full length of the protein
and nuclear magnetic resonance (NMR). The resulting
data indicate that Hlp interacts with heparan sulfate
through two distinct regions located, respectively, in the
N-terminal and C-terminal domains of the protein.
Results
Binding of Hlp synthetic peptides to heparan sulfate
In a previous study, truncated recombinant Hlp molecules
were tested and it was demonstrated that the highly posi-
tive C-terminal region of the protein is involved in its
binding to extracellular matrix components and its capac-
ity to act as an adhesin [12]. To refine and confirm these
data, a panel of overlapping 30-mer synthetic peptides
covering the entire sequence of Hlp was immobilized in
microtiter-plate wells. The peptides were, then, incubated
with biotinylated heparin or heparan sulfate in phosphate
buffer 10 mM pH 7.2 and their binding capacity was mon-
itored by the addition of streptavidin peroxidase. The list
of Hlp peptides with their corresponding amino acid
sequences and pI shown in Table 1. As shown in Figure
1A, heparan sulfate bound to peptides covering the C-ter-
minal region of the protein. Among the peptides derived
from the N-terminal region, detectable binding of bioti-
nylated heparan sulfate was only observed in wells coated
with p31–60 and p46–75. Although the signal with these
peptides was low, this was a consistent result observed in
six independent experiments. An identical binding pat-
tern was observed when biotinylated heparin was used
instead of heparan sulfate (data not shown). The binding
of the peptides covering the C-terminal region is in agree-
ment with previous results demonstrating that rHlp-C
(from Ala110 to Lys200), but not rHlp-N (covering the
first 109 Hlp amino acids), was able to bind heparan sul-
fate in a similar solid-phase assay [12]. Moreover, the
binding of p31–60 is in agreement with the Hlp heparin-
binding region between Thr31 and Phe50 defined by Aoki
et al, 2004 [9]. However, the binding of p46–75 suggested
an additional binding region.
Effect of salt concentrations on the binding of Hlp 
peptides to heparan sulfate in microplate assays
All peptides that showed heparan sulfate-binding activity
are rich in basic amino acid residues. To investigate
whether Hlp-heparin/heparan sulfate interactions areBMC Microbiology 2008, 8:75 http://www.biomedcentral.com/1471-2180/8/75
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mediated by electrostatic forces involving the negatively
charged sulfate and carboxyl groups of heparin and
heparan sulfate with the positively charged residues of
Hlp, binding assays were performed in the presence of
increasing concentrations of NaCl. As can be seen in Fig-
ure 1B, for p31–60, p46–75, p136–165, and p151–180
and the entire Hlp protein, significant binding inhibition
was achieved with increasing concentrations of NaCl,
indicating the involvement of electrostatic forces in these
interactions.
Binding of p31–60, p136–165, and p151–180 to heparin-
Sepharose
The binding capacity of p31–60, p136–165, and p151–
180 was also analyzed by affinity chromatography on a
column of heparin-Sepharose. Individual peptides were
applied to a heparin-Sepharose column and subsequently
eluted with a 0–2 M NaCl gradient. Figure 2 shows the
elution profile and the salt concentration necessary for
elution of each peptide. Peptides p31–60, p36–165, and
p151–180 bound to the column and were eluted at 1.09,
1.31, and 1.29 M NaCl, respectively, confirming their
heparin-binding capacity.
Analysis of the interaction of Hlp peptides with heparan 
sulfate by STD-NMR
To further elucidate the basis of Hlp and glycosaminogly-
can interaction, the complexes between the peptides p16–
45, p31–60, p46–75, p136–165, p151–180, and heparan
sulfate were studied using Saturation Transfer difference –
(STD)-NMR experiments. This technique allows for the
identification of protons from a ligand molecule in con-
tact with a macromolecule. Resonances of the oligosac-
charide were selectively saturated and the spectrum was
subtracted from a reference spectrum from which the
heparan sulfate was not saturated. Lastly, the enhance-
ments were observed in the difference (STD) spectrum
[13,14]. Protons of the ligand peptide, which were in
close contact with heparan sulfate, received the highest
degree of saturation and were easily identified within the
STD spectrum.
NMR experiments confirmed the heparan-sulfate binding
capacity of p31–60, p46–75, p136–165, p51–180, and
the inability of p16–45 to do so. Figure 3 shows the refer-
ence TOCSY spectrum (Figure 3A) of heparan sulfate (100
μg) in the presence of 2 mM p16–45. The difference in the
Total Correlation Spectroscopy – (TOCSY)-STD spectrum
obtained (Figure 3B) shows no signal, indicating that pep-
tide p16–45 does not bind to heparan sulfate, thus pro-
viding a negative control with no specific interaction with
the macromolecule. Nevertheless, Figure 4 shows a clear
interaction between peptide p31–60 and heparan sulfate.
Figure 4A shows the cross peaks of the ligand protons
involved in the formation of the complex. A close analysis
of the STD spectrum shows a correlation among the δH at
3.18 ppm, βH and γH at 1.85, and 1.65 ppm, respectively,
suggesting that at least one of the Arg residues is in close
contact with heparan sulfate. In addition, it is evident that
the magnetization is also transferred to the γCH3 of Val.
Figure 4B provides evidence of the interaction of Phe res-
idues with heparan sulfate. From the cross peaks at 3.19,
3.22 ppm (δH) and those at 1.89 (βH) and 1.63 ppm (γH)
assigned in Figure 4C, it is evident that heparan sulfate
binds to the Arg (R) residues of p46–75. The interaction
of the amino acid Val (V) is evidenced by signals at 0.89
Hlp peptides corresponding to the C-terminal domain bind  heparan sulfate Figure 1
Hlp peptides corresponding to the C-terminal 
domain bind heparan sulfate. (A) Microtiter-plate wells 
coated with 50 μL of 0.1 μM Hlp or 50 μL of 0.65 μM individ-
ual 30-mer synthetic peptides covering the entire sequence 
of Hlp were incubated with biotinylated heparan sulfate in 
phosphate buffer 10 mM, pH 7.2. Heparan sulfate binding was 
measured by adding streptavidin peroxidase to the wells and 
expressed in absorbency units at 490 nm. The data are 
expressed as mean ± SD of a representative experiment 
from five independent ones performed in duplicate. (B) 
Microtiter-plate wells were coated with Hlp or peptides 
p31–60, p136–165, and p151–180 and biotinylated heparan 
sulfate was added in the presence of increasing concentra-
tions of NaCl. Heparan sulfate binding was quantified as 
above.BMC Microbiology 2008, 8:75 http://www.biomedcentral.com/1471-2180/8/75
Page 4 of 10
(page number not for citation purposes)
and 1.41 ppm. Furthermore, the interaction of at least one
of the Thr (T) residues is evidenced by the resonances aris-
ing from γCH3 (1.29 ppm), βH (3.96 ppm), and αH (4.15
ppm).
Figure 5A shows that the peptide p136–165 binds to
heparan sulfate. The STD spectrum demonstrates that the
amino acids involved in contact with the macromolecule
were Lys (3.02, 2.99, 1.73, and 1.38 ppm), and the hydro-
phobic residue Ile146 (γCH3, 0.96 ppm, and γH, 1.23 and
1.38 ppm). Finally, the STD-TOCSY spectrum in Figure 5B
shows the amino acid Lys from the peptide p151–180
receiving the highest saturation transferance from
heparan sulfate.
Discussion
It is well established that adhesion of bacteria to target
host tissues is required for colonization and subsequent
development of disease [15]. Since adherence is a key step
in microbial pathogenesis, the use of anti-adhesion ther-
apy and anti-adhesion immunity has emerged as an
attractive approach toward the development of new tools
to control infectious diseases [16]. In order to develop
anti-adhesive drugs, including adhesin-based vaccines, a
detailed understanding of the mechanisms by which
microorganisms initiate host cell colonization is neces-
sary. It has been reported that Hlp is a pivotal adhesion
molecule in the context of mycobacteria interaction with
host cells. It was initially described as a laminin-binding
protein whose function was to mediate M. leprae adhesion
to Schwann cells in conjunction with PGL-I, another lam-
inin-binding molecule present on the surface of M. leprae
[6,7,17]. Later on, the capacity of Hlp to bind heparin/
heparan sulfate became evident along with the relevance
of this interaction in the context of M. tuberculosis attach-
ment to respiratory epithelial cells and the potential
involvement of this protein in the initial events of host
colonization [8,9,12].
Due to the emergence of Hlp as a key component in myco-
bacterial pathogenesis, a detailed analysis of the molecu-
lar regions involved in the interaction with extracellular
matrix components was initiated. The first investigation
in this direction reported that the region between Thr31
and Phe50 was responsible for the interaction of Hlp with
heparin [9]. However, we recently showed that a fragment
of the protein corresponding to the last 91 amino acids
was additionally able to bind heparan sulfate [12]. To fur-
ther define the heparan sulfate-binding sites of Hlp in the
present study, a panel of 30-mer synthetic peptides
Table 1: Amino acid sequence and pI values of Hlp synthetic peptides. Basic amino acids are in bold.
Peptide Amino acid sequence pI
p1 1MNKAELIDVLTQKLGSDRRQATAAVENVVD30 5.00
p2 16SDRRQATAAVENVVDTIVRAVHKGDSVTIT45 6.48
p3 31TIVRAVHKGDSVTITGFGVFEQRRRAARVA60 11.83
p4 46GFGVFEQRRRAARVARNPRTGETVKVKPTS75 12.01
p5 61RNPRTGETVKVKPTSVPAFRPGAQFKAVVA90 11.73
p6 76VPAFRPGAQFKAVVAGAQRLPLEGPAVKRG105 11.72
p7 91GAQRLPLEGPAVKRGVATSAAKKAAIKKAP120 11.22
p8 106VATSAAKKAAIKKAPVKKALAKKAATKAPA135 10.90
p9 121VKKALAKKAATKAPAKKAVKAPAKKITTAV150 10.95
p10 136KKAVKAPAKKITTAVKVPAKKATKVVKKVA165 11.00
p11 151KVPAKKATKVVKKVAAKAPVRKATTRALAK180 10.70
p12 166AKAPVRKATTRALAKKAAVKKAPAKKVTAA195 12.06
p13 181KAAVKKAPAKKVTAAKRGRK200 12.05
Elution profiles of p31–60, p136–165, and p151–180 from a  Heparin-Sepharose affinity colunm Figure 2
Elution profiles of p31–60, p136–165, and p151–180 
from a Heparin-Sepharose affinity colunm. Individual 
peptides bound to the column were eluted with a 0 – 2 M 
gradient of NaCl. Peptides p31–60, p136–165, and p151–180 
were eluted, respectively, at 1.09, 1.31, and 1.29 M NaCl.BMC Microbiology 2008, 8:75 http://www.biomedcentral.com/1471-2180/8/75
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derived from the entire sequence of this adhesin was used.
Three distinct assays were employed to map the regions of
Hlp/LBP involved with heparin/heparan sulfate interac-
tion: solid phase assays in microplates, heparin-Sepharose
affinity chromatography, and NMR. The results obtained
indicate that Hlp interacts with heparin/heparan sulfate in
two distinct regions: one located at the N-terminal half of
the protein between residues 31 and 60, and the other cor-
responding to the entire C-terminal half of the protein.
The features of Hlp heparan sulfate-binding regions
herein defined are typical of heparin-binding consensus
sequences. As such, they were expected to interact with
GAGs (for review, see [18]. The definition of the first site
was based on the capacity of peptides p31–60 and p46–
75 to bind heparin and heparan sulfate using three differ-
ent assays. These overlapping peptides share the
QRRRAAR sequence (residues 52 to 59) that fits perfectly
into the heparin-binding consensus XBBBXXB sequence
(where X is an hydropathic amino acid and B is a basic res-
idue) previously defined by Cardin and Weintraub [18].
NMR experiments confirmed that p31–60 and p46–75,
but not p16–45, were able to bind heparan sulfate. More-
over, peptide p31–60 was also able to bind tightly to a
heparin-agarose column with elution only occurring at
high salt concentrations.
A second GAG-binding region was characterized at the
Hlp C-terminal. The 30-mer synthetic peptides p91–120,
p106–135, p121–150, p136–165, p151–180, p166–195,
and the 20-mer peptide p181–200 covering the C-termi-
nal region of M. leprae Hlp were also able to bind heparin/
heparan sulfate in solid phase assays. Two of these pep-
tides, p136–165 and p151–180, were also tested for their
capacity to bind heparin and heparan sulfate in affinity
chromatography and NMR, respectively. As a result, their
GAG-binding activity was confirmed. All peptides of this
region are rich in positively charged residues (from 7 to 11
residues per peptide, mainly Lys), which occur singly or in
clusters of two, mostly intercalated with Ala/Val residues.
This same spacing pattern of basic amino acids has been
found in several heparin-binding domains and seems to
facilitate formation of ion pairs with spatially-defined
sulfo- or carboxyl-groups in GAGs [19].
Direct NMR observation of the side chain proton reso-
nances that are perturbed upon heparin binding has
proven to be a powerful method of identifying the amino
acids involved in protein-GAG interaction [20]. However,
to our knowledge, this is the first time that STD-NMR has
been applied to study the interaction of a ligand (a syn-
thetic peptide) with a nonproteic macromolecule
(heparan sulfate). Analysis of the interaction of p31–60,
p46–75, p136–165, and p151–180 with heparan sulfate
by STD-NMR led the way to identifying Arg, Val, Thr, Phe,
STD-TOCSY of p16–45 in presence of heparan sulfate Figure 3
STD-TOCSY of p16–45 in presence of heparan sul-
fate. (A) Reference TOCSY spectrum of p16–45 (2 mM) in 
the presence of heparan sulfate (10 μM). (B) STD-TOCSY 
spectrum. Spectra were recorded in PBS-D2O, pH 7.6, 25°C 
with mixing time of 66 ms, 32 scans per t1 increment. 200 
increments were collected in an interlaced mode for on or 
off pre-saturation.BMC Microbiology 2008, 8:75 http://www.biomedcentral.com/1471-2180/8/75
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Lys, and Ile as the amino acid residues directly involved in
Hlp-GAG interaction.
The heparin-binding regions for M. leprae Hlp herein
described only coincide partially with the one previously
reported in M. bovis Hlp (so-called MDP1) [9]. These
authors indicated that the sequence between Thr31 and
Phe50 was the only heparin-binding site present in
MDP1, excluding the cluster of Arg53, Arg54, Arg55, and
Arg57 as well as the heparin-binding C-terminal domain
of the protein. Their finding was based solely on solid
phase assays in microplates using 20-mer synthetic pep-
tides covering the entire length of the protein; and no
additional experiments based on different techniques
were performed to confirm these results. Moreover, the
discrepancy between the Hlp heparin-binding sites can-
not be explained by the fact that the Hlp proteins ana-
lyzed in both studies originated from different
mycobacterial species. As shown in Figure 6, M. leprae and
M. bovis BCG Hlp are 84% identical in their amino acid
Association of peptides p31–60 and p46–75 with heparan sulfate Figure 4
Association of peptides p31–60 and p46–75 with heparan sulfate. (A) STD-TOCSY of p31–60 (2 mM) in the presence 
of heparan sulfate (10 μM). (B) STD-TOCSY spectrum of the aromatic region. (C) STD-TOCSY of p46–75 (2 mM) in the pres-
ence of heparan sulfate (10 μM). Spectra were recorded as in Figure 3.BMC Microbiology 2008, 8:75 http://www.biomedcentral.com/1471-2180/8/75
Page 7 of 10
(page number not for citation purposes)
sequences. Actually, a multiple sequence alignment shows
that the N-terminal heparin-binding region described in
this study in addition to the one defined by Aoki et al [9]
are conserved in all mycobacterial Hlp homologues
sequenced to date (data not shown). Variations in Hlp
sequences among mycobacterial homologues are mostly
located at the C-terminal region even though the features
recognized as important for heparin binding seem to be
preserved across the species.
In summary, based on this study and previous observa-
tions [9,12], we propose that there are two distinct
heparan sulfate-binding regions in Hlp: region I, from
Thr31 to Ala60 and region II, spanning Lys103 to Lys200
(Figure 6). The identification of Arg in region I and Lys in
region II confirms the critical participation of positively
charged residues and electrostatic forces in mediating
GAG-protein interaction. Moreover, NMR observations
showed the direct involvement of Val, Thr, and Phe in
region I and Ile in region II, indicating that specific noni-
onic interactions also take part in Hlp-heparan sulfate
binding. As has been observed in other GAG-protein
interactions, it is almost certain that these residues interact
with N-acetyl and hydroxyl groups in heparan sulfate
through hydrophobic interactions and hydrogen bond-
ing, respectively, [18].
Reinforcing the role of the highly positive C-terminal
domain in the interaction of Hlp with heparin/heparan
sulfate, the heparin binding hemagglutinin (HBHA),
another adhesin implicated in the interaction of mycobac-
teria with epithelial cells [21], also contains lysine-rich
Association of peptides p136–165 and p151–180 with heparan sulfate Figure 5
Association of peptides p136–165 and p151–180 with heparan sulfate. (A) STD-TOCSY of p136–165 (2 mM) in asso-
ciation with heparan sulfate (100 μg). (B) STD-TOCSY of p151–180 (2 mM) in the presence of heparan sulfate (10 μM). Spec-
tra were recorded as in Figure 3.BMC Microbiology 2008, 8:75 http://www.biomedcentral.com/1471-2180/8/75
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motifs in the C-terminal domain (from Lys161 to Lys199;
Figure 6) that have been shown to mediate bacterial
adherence via interaction with heparan sulfate-containing
proteoglycans [22,23]. HBHA appears, however, to inter-
act with heparin/heparan sulfate more weakly than Hlp
[9], suggesting it plays a secondary role in adhesion.
Indeed, as shown in this study, Hlp displays an expanded
C-terminal GAG-binding domain and an additional
heparin-binding region at the N-terminal domain when
compared to HBHA, which may explain the higher affin-
ity of Hlp to GAGs (Figure 6).
Conclusion
The results obtained indicate that Hlp interacts with
heparin/heparan sulfate in two distinct regions: one
located at the N-terminal half of the protein between res-
idues 31 and 60, and the other corresponding to the entire
C-terminal half of the protein. Both heparan sulfate-bind-
ing regions are preserved in all mycobacterial Hlp homo-
logues that have been sequenced, suggesting important
but possibly divergent roles for this surface-exposed pro-
tein in both pathogenic and saprophic species. Due to the
emergence of Hlp as a key component in mycobacterial
pathogenesis, and the potential involvement of this pro-
tein in the initial events of host colonization, a detailed
analysis of the molecular regions involved in the interac-
tion with extracellular matrix components may contribute
to the development of new prophylaxis and therapeutic
interventions in mycobacterial diseases based on this
adhesin.
Methods
M. leprae Recombinant Hlp and Peptides
Recombinant (r) M. leprae Hlp was obtained, as previ-
ously described [7]. Twelve 30-mer peptides, overlapping
by fifteen amino acids and covering Met1 to Ala195 of M.
leprae  Hlp and one 20-mer peptide, corresponding to
Lys181 to Lys200 of the protein, were synthesized by
using solid-phase pin technology (Mimotopes, San
Diego, CA, USA). Each peptide was dissolved in distilled
water at a concentration of 10 mg/mL and stored frozen at
-20°C until use.
Solid-phase binding assays
Wells of a 96-well of polystyrene microtiter-plates (Corn-
ing, New York, NY, USA) were coated with 50 μL of Hlp
(0.1 μM) or synthetic peptides (0.65 μM) in 0.1 M carbon-
ate buffer pH 9.6. Plates were incubated overnight at 4°C.
The wells were then washed with 10 mM of phosphate
buffer pH 7.2 and blocked for 2 h with 200 μL of phos-
phate buffer-2% bovine serum albumin (BSA) at room
temperature. Upon washing with phosphate buffer/
0.05% Tween 20, 50 μL of 25 or 50 μg/mL of biotinylated
heparin (Sigma) or 10 μg/mL of heparan sulfate (Sigma)
in phosphate buffer with increasing NaCl concentration
(0, 125, 200 and 400 mM) were added to the wells and
incubation was performed at room temperature for 2 h.
The wells were rinsed with phosphate buffer/Tween 20
and incubated with 50 μL of streptavidin-peroxidase
(Pierce, Rockford, IL, USA) at 0.5 μg/mL. Peroxidase activ-
ity was revealed with hydrogen peroxide and O-phenylen-
ediamine (OPD). The reaction was stopped with HCl and
read at 490 nm using an automatic microplate scanning
spectrophotometer (SpectraMAX 190; Molecular Devices
Corp, Sunnyvale, CA, USA).
Protein sequence alignment of Hlp from M. leprae, and MDP1 and HBHA from M. tuberculosis Figure 6
Protein sequence alignment of Hlp from M. leprae, and MDP1 and HBHA from M. tuberculosis. The sequence of 
Hlp and MDP1 surrounded by the black straight-lined box corresponds to the heparin-interacting region (region I) proposed in 
this study. The sequence underlined by a red line represents the other heparin-interacting region (region II). The heparin-bind-
ing domain of M. tuberculosis HBHA is also shown on the bottom. The sequence alignment was prepared via the Jalview Java 
Alignment Editor version 2.2 [26].BMC Microbiology 2008, 8:75 http://www.biomedcentral.com/1471-2180/8/75
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NMR Experiments
Peptides p16–45, p31–60, p46–75, p136–165, p151–180
(2 mM final concentration), and heparan sulfate (10 μM)
were dissolved in deuterated phosphate buffered saline
(PBS), pH 7.6 (not correct for isotope effects). NMR spec-
tra were obtained at a temperature probe of 25°C on a
Bruker DMX 600 equipped with a 5-mm triple resonance
probe.
Saturation Transfer Difference (STD)
TOCSY-STD spectra correspond to a modified TOCSY
sequence [24,25]. Spectra were recorded with a mixing
time of 66 ms, 32 scans per t1 increment with pre-satura-
tion on or off for 2 s. The on-resonance irradiation at the
heparan sulfate was applied at a chemical shift of 5.5 ppm
(where protein signals from all peptides were not
observed). Off-resonance irradiation was applied at 30
ppm (where no signals were observed). Samples contain-
ing only the peptides were used as controls and did not
show any STD effect, since the resulting diference spec-
trum did not contain any signal for the peptide. Two hun-
dred t2 increments were collected in an interlaced mode
after every on- and off-irradiation spectra to minimize
artifacts arising from temperature and magnet instability.
Prior to subtraction, both spectra were identically proc-
essed and phased. The acquisition time for the two-
dimensional experiments was typically 16 h. The spectra
were apodized with a square cosine bell function in both
dimensions and zero-filled twice.
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